Kiniksa Pharmaceuticals International (KNSA) Enterprise Value (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Enterprise Value came in at -$525.9 million in Q2 2026, down 24.18% YoY from -$693.6 million in Q2 2025, and down 12.36% on a QoQ basis from -$468.1 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Enterprise Value (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Enterprise Value data on file, last reported at -$525.9 million in Q2 2026.
- Quarterly Enterprise Value fell 24.18% year-over-year to -$525.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$525.9 million (down 24.18% YoY) and the FY2025 annual result came in at -$414.1 million, down 69.96% from the prior year.
- Enterprise Value eased to -$525.9 million in Q2 2026, from -$468.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$138.2 million in Q2 2022 to a low of -$529.3 million in Q3 2025.
- A 5-year average of -$309.4 million and a median of -$285.2 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value surged 64.34% — and 2023, when it slumped 86.25%.
- Tracing KNSA's Enterprise Value over 5 years: stood at -$190.6 million in 2022, then decreased by 8.27% to -$206.4 million in 2023, then slipped by 18.05% to -$243.6 million in 2024, then tumbled by 69.96% to -$414.1 million in 2025, then dropped by 27.01% to -$525.9 million in 2026.
- The last three Enterprise Value figures came in at -$525.9 million (Q2 2026), -$468.1 million (Q1 2026), and -$414.1 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -882.82 Mn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -3.65 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -5.79 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -2.66 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -886.50 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -389.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | -164.00 Mn |
| 10 | Kiniksa Pharmaceuticals International | 6.09 Bn | 5.57 Bn | 220.03 Mn | -525.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -525.93 Mn |
| Mar 31, 2026 | -468.09 Mn |
| Dec 31, 2025 | -414.07 Mn |
| Sep 30, 2025 | -529.35 Mn |
| Jun 30, 2025 | -423.53 Mn |
| Mar 31, 2025 | -379.55 Mn |
| Dec 31, 2024 | -243.63 Mn |
| Sep 30, 2024 | -350.18 Mn |
| Jun 30, 2024 | -338.25 Mn |
| Mar 31, 2024 | -286.03 Mn |
| Dec 31, 2023 | -206.37 Mn |
| Sep 30, 2023 | -284.34 Mn |
| Jun 30, 2023 | -257.42 Mn |
| Mar 31, 2023 | -187.49 Mn |
| Dec 31, 2022 | -190.61 Mn |
| Sep 30, 2022 | -200.72 Mn |
| Jun 30, 2022 | -138.21 Mn |
| Mar 31, 2022 | -145.58 Mn |
| Dec 31, 2021 | -182.20 Mn |
| Sep 30, 2021 | -210.18 Mn |